Table_1_Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.docx by Yanhong Guo (270212)

“…Among those 247 patients with MHD, 211 patients were already in treatment with angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs) before being treated with sacubitril/valsartan. We also performed an analysis to compare the differences between the 211 patients who had previously received ACEi/ARB treatment and the 36 patients who were sacubitril/valsartan naive.…”

A single systemic prophylactic treatment with CpG-C results in long-term reduction of metastatic burden in the brain. by Amit Benbenishty (6524375)

“…<p>(<b>a</b>) In the experimental metastasis models, we used the aECAi approach [<a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.2006859#pbio.2006859.ref032" target="_blank">32</a>] for injection of tumor cells (see <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.2006859#sec002" target="_blank">Methods</a>): a method that improves brain targeting and preserves cerebral hemodynamics. …”

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021 by Stein Emil, Vollset

Get full text
Get full text
Get full text

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021 by Stein Emil, Vollset

Get full text
Get full text
Get full text

Global, regional, and national burden of HIV/AIDS, 1990–2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021 by Austin, Carter

“…In the same period, PUV increased in central Europe, eastern Europe, and central Asia by 116·1% (8·0–218·2). Our forecasts predict a continued global decline in HIV incidence and mortality, with the number of people living with HIV peaking at 44·4 million (40·7–49·8) by 2039, followed by a gradual decrease. …”
Get full text
Get full text
Get full text

PDLB - Balance Sheet by Nguyen Linh (19516642)

“…</p><p><br></p><p dir="ltr">ECIP capital: PDLB received $225M of ECIP capital, and the regulators assigned them the lowest possible dividend (0.5%) on this capital for the first year of payments (announced in June). If we assume PDLB continues to pay 0.5% on this preferred and they have a cost of preferred equity of 10%, then we can calculate the value of this $225M liability as just $11M, with the rest a write-up to equity.…”

Supplemental data of Glucocorticoid Dependent Mesenchymal Cell Differentiation is Required for Perinatal Lung Morphogenesis and Lung Function by Yan Xu (6655778)

“…Cells were pelleted, counted and 50,000 cells per sample prepared for ATAC-seq at a depth of ~1,000,000 reads per sample. …”

Single-cell-resolution analysis of RPE flatmounts revealed only minor changes to cellular morphology. by Viola Kretschmer (485828)

“…Analysis of cell size revealed a modest increase in cell size in the mutant starting from P29 onwards, while AR was decreasing. …”

The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 by Khanh Bao, Tran

“…BackgroundUnderstanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. …”
Get full text
Get full text
Get full text